Effect of intravitreal aflibercept injection for age-related macular degeneration with a retinal pigment epithelial tear refractory to intravitreal ranibizumab injection

Effect of intravitreal aflibercept injection for age-related macular degeneration with a retinal pigment epithelial tear refractory to intravitreal ranibizumab injection

Ayaka Fujii,1 Hisanori Imai,1,2 Michiko Kanai,1 Atsushi Azumi1,2 1Department of Ophthalmology, Kobe Kaisei Hospital, 2Department of Organ Therapeutics, Division of Ophthalmology, Kobe University Graduate School of Medicine, Kobe, Japan Background: The purpose of this study was to evaluate the ef...

Descripción completa

Guardado en:
Detalles Bibliográficos
Autores principales: Fujii A, Imai H, Kanai M, Azumi A
Formato: article
Lenguaje:EN
Publicado: Dove Medical Press 2014
Materias:
Ophthalmology
RE1-994
Acceso en línea:https://doaj.org/article/7b638b7a83ee4952bc6c47300010658d
Etiquetas: Agregar Etiqueta
Sin Etiquetas, Sea el primero en etiquetar este registro!
id oai:doaj.org-article:7b638b7a83ee4952bc6c47300010658d
record_format dspace
spelling oai:doaj.org-article:7b638b7a83ee4952bc6c47300010658d2021-12-02T06:54:40ZEffect of intravitreal aflibercept injection for age-related macular degeneration with a retinal pigment epithelial tear refractory to intravitreal ranibizumab injection1177-5483https://doaj.org/article/7b638b7a83ee4952bc6c47300010658d2014-06-01T00:00:00Zhttp://www.dovepress.com/effect-of-intravitreal-aflibercept-injection-for-age-related-macular-d-a17334https://doaj.org/toc/1177-5483 Ayaka Fujii,1 Hisanori Imai,1,2 Michiko Kanai,1 Atsushi Azumi1,2 1Department of Ophthalmology, Kobe Kaisei Hospital, 2Department of Organ Therapeutics, Division of Ophthalmology, Kobe University Graduate School of Medicine, Kobe, Japan Background: The purpose of this study was to evaluate the effects of intravitreal aflibercept injection for age-related macular degeneration (AMD) with a retinal pigment epithelial (RPE) tear after intravitreal ranibizumab injection (IVR) which finally became resistant to additional IVR. Methods: We reviewed the medical records of AMD patients with RPE tears after intravitreal ranibizumab injection who were treated with intravitreal aflibercept injection after acquisition of resistance to additional IVR. Results: One eye from three patients, aged 66, 77, and 78 years, was evaluated. All cases started treatment with IVR for AMD. RPE tear developed 1, 4, and 3 months after the first IVR, respectively. Additional IVR was performed seven, seven, and nine times over 10, 19, and 21 months, respectively, but all cases finally became resistant to IVR. Intravitreal aflibercept injection was performed four times, six times, and once over 8, 9, and 6 months, respectively. At the last visit, all patients had complete resolution of subretinal and intraretinal fluid. Conclusion: Continued intravitreal aflibercept injection may be beneficial to manage AMD with RPE tear which has become resistant to additional IVR. Keywords: aflibercept, ranibizumab, retinal pigment epithelial tear, age-related macular degenerationFujii AImai HKanai MAzumi ADove Medical PressarticleOphthalmologyRE1-994ENClinical Ophthalmology, Vol 2014, Iss default, Pp 1199-1202 (2014)
institution DOAJ
collection DOAJ
language EN
topic Ophthalmology
RE1-994
spellingShingle Ophthalmology
RE1-994
Fujii A
Imai H
Kanai M
Azumi A
Effect of intravitreal aflibercept injection for age-related macular degeneration with a retinal pigment epithelial tear refractory to intravitreal ranibizumab injection
description Ayaka Fujii,1 Hisanori Imai,1,2 Michiko Kanai,1 Atsushi Azumi1,2 1Department of Ophthalmology, Kobe Kaisei Hospital, 2Department of Organ Therapeutics, Division of Ophthalmology, Kobe University Graduate School of Medicine, Kobe, Japan Background: The purpose of this study was to evaluate the effects of intravitreal aflibercept injection for age-related macular degeneration (AMD) with a retinal pigment epithelial (RPE) tear after intravitreal ranibizumab injection (IVR) which finally became resistant to additional IVR. Methods: We reviewed the medical records of AMD patients with RPE tears after intravitreal ranibizumab injection who were treated with intravitreal aflibercept injection after acquisition of resistance to additional IVR. Results: One eye from three patients, aged 66, 77, and 78 years, was evaluated. All cases started treatment with IVR for AMD. RPE tear developed 1, 4, and 3 months after the first IVR, respectively. Additional IVR was performed seven, seven, and nine times over 10, 19, and 21 months, respectively, but all cases finally became resistant to IVR. Intravitreal aflibercept injection was performed four times, six times, and once over 8, 9, and 6 months, respectively. At the last visit, all patients had complete resolution of subretinal and intraretinal fluid. Conclusion: Continued intravitreal aflibercept injection may be beneficial to manage AMD with RPE tear which has become resistant to additional IVR. Keywords: aflibercept, ranibizumab, retinal pigment epithelial tear, age-related macular degeneration
format article
author Fujii A
Imai H
Kanai M
Azumi A
author_facet Fujii A
Imai H
Kanai M
Azumi A
author_sort Fujii A
title Effect of intravitreal aflibercept injection for age-related macular degeneration with a retinal pigment epithelial tear refractory to intravitreal ranibizumab injection
title_short Effect of intravitreal aflibercept injection for age-related macular degeneration with a retinal pigment epithelial tear refractory to intravitreal ranibizumab injection
title_full Effect of intravitreal aflibercept injection for age-related macular degeneration with a retinal pigment epithelial tear refractory to intravitreal ranibizumab injection
title_fullStr Effect of intravitreal aflibercept injection for age-related macular degeneration with a retinal pigment epithelial tear refractory to intravitreal ranibizumab injection
title_full_unstemmed Effect of intravitreal aflibercept injection for age-related macular degeneration with a retinal pigment epithelial tear refractory to intravitreal ranibizumab injection
title_sort effect of intravitreal aflibercept injection for age-related macular degeneration with a retinal pigment epithelial tear refractory to intravitreal ranibizumab injection
publisher Dove Medical Press
publishDate 2014
url https://doaj.org/article/7b638b7a83ee4952bc6c47300010658d
work_keys_str_mv AT fujiia effectofintravitrealafliberceptinjectionforagerelatedmaculardegenerationwitharetinalpigmentepithelialtearrefractorytointravitrealranibizumabinjection
AT imaih effectofintravitrealafliberceptinjectionforagerelatedmaculardegenerationwitharetinalpigmentepithelialtearrefractorytointravitrealranibizumabinjection
AT kanaim effectofintravitrealafliberceptinjectionforagerelatedmaculardegenerationwitharetinalpigmentepithelialtearrefractorytointravitrealranibizumabinjection
AT azumia effectofintravitrealafliberceptinjectionforagerelatedmaculardegenerationwitharetinalpigmentepithelialtearrefractorytointravitrealranibizumabinjection
_version_ 1718399699172458496

Ejemplares similares